The efficacy of 6-month or 12-month icotinib following chemotherapy compared to chemotherapy alone in patients with resected stage IIA-IIIA NSCLC harboring an EGFR mutation is currently under evaluation in the ICTAN trial (NCT01996098). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.